| Document |
Document Title |
|
WO/2023/249965A1 |
The present application relates to compounds of Formula (I), Formula (II), and Formula (III) and to pharmaceutically acceptable salts and solvates of any of the foregoing, as well as pharmaceutical compositions and methods of using same ...
|
|
WO/2023/247593A1 |
The disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprising compounds of formula (I), as well as methods of their use and preparation, are also described.
|
|
WO/2023/247590A1 |
The disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprising compounds of formula (I), as well as methods of their use and preparation, are also described.
|
|
WO/2023/247047A1 |
The present invention refers to a peptide, comprising or consisting of SEQ ID NO: 1 (CAYMTMKIRN), for use as a medicament, preferably in the prevention and/or treatment of cardiac damage arising after ischemia followed by reperfusion, or...
|
|
WO/2023/249105A1 |
The purpose of the present invention is to provide a therapeutic agent or a preventive agent for drug-induced myocardial disorders and having ferroptosis inhibitory action. The present invention provides a therapeutic agent or a preven...
|
|
WO/2023/250327A1 |
Metabolic disorders such as liver disorders and cardiovascular disorders are widely abundant, and may affect a wide variety of people. Improved therapeutics are needed for treating these disorders. Disclosed herein are compositions compr...
|
|
WO/2023/246732A1 |
Disclosed are a benzoheterocyclic substituted tetrahydroisoquinoline compound salt form and a preparation method therefor. Specifically, disclosed are an amorphous form and salt form of the compound as shown in formula (I), and a use the...
|
|
WO/2023/246876A1 |
The present invention provides the following compound (I) or a pharmaceutically acceptable salt, an ester, an optical isomer, a tautomer, a stereoisomer, a polymorph, a solvate, an N-oxide, an isotope-labeled compound, a metabolite, a ch...
|
|
WO/2023/240379A1 |
Provided in the present invention are an imidazolinone derivative and the use thereof. The imidazolinone derivative is a compound having a structure as shown in the following formula (I) or (II) or a pharmaceutically acceptable salt, ste...
|
|
WO/2023/241591A1 |
Provided are a small interfering RNA (siRNA) used to inhibit the expression of proprotein convertase subtilisin/kexin type 9 (PCSK9) in a cell, a vector comprising nucleotides encoding same, and a cell, as well as a method using the siRN...
|
|
WO/2023/241688A1 |
The present invention relates to a composition for treating and resisting blood coagulation and use thereof, and particularly relates to a pharmaceutical composition containing (7aS, 2'S)-2-oxo-clopidogrel and use thereof. The present in...
|
|
WO/2023/244738A1 |
Methods for treating a disease, condition, or disorder associated with impaired muscle regeneration, including a muscular dystrophy, such as Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD), or limb-girdle muscular d...
|
|
WO/2023/244554A1 |
Provided are compounds of the Formula (I), or their pharmaceutically acceptable salts, wherein X1, X2, X3, A1, A2, R1-R7, R8a, R8b, R9a, R9b, R10 and R11 are as herein described. (I) can trap IL-1β and are expected to have utility as th...
|
|
WO/2023/242440A1 |
A method for stimulation of maturation and/or differentiation of lung tissue in a preterm infant and/or method of treatment or prophylaxis of respiratory distress syndrome in a preterm infant (also referred to a neonate herein), a low bi...
|
|
WO/2023/242439A1 |
A method of treatment or prophylaxis comprising stabilising blood pressure and/or flow in a preterm infant (also referred to a neonate herein) by administering a therapeutic amount of a composition comprising IGF-1 and an IGF binding pro...
|
|
WO/2023/240958A1 |
The present invention relates to a use of a JWA polypeptide in preparation of a drug for resisting a neovascular ocular disease. The amino acid sequence of the polypeptide is shown as I or II: I: FPGSDRF-Z; II: X-FPGSDRF-Z, wherein an am...
|
|
WO/2023/239892A1 |
Provided herein are methods of modulating CD68, or treating CD68-associated disorders, by using a compound as disclosed herein.
|
|
WO/2023/237577A1 |
The invention relates to soluble guanylate cyclase (sGC) activators, preferably (3S)-3-(4-chloro-3- {[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoy
l]amino}phenyl)-3-cyclopropylpropanoic acid (runcaciguat) and / or substitut...
|
|
WO/2023/237661A1 |
Aortic valve stenosis (AS), is the most frequent valvular heart disease in Europe and affects more than 1 in 4 people over 65 years old. AS progression from fibrotic thickening to valvular leaflets calcification leads to heart failure de...
|
|
WO/2023/236778A1 |
The present invention relates to a trifunctional compound, comprising at least one covalent warhead capable of forming a reversible or irreversible covalent linkage with a protein or tissue. The present invention further relates to a pha...
|
|
WO/2023/240062A1 |
Provided herein, inter alia, are melanopsin variants that demonstrate greater amplitude/conductance and/or faster off kinetics than the amplitude/conductance and/or the off kinetics of the wild type human melanopsin. Also provided are re...
|
|
WO/2023/238955A1 |
The present invention pertains to a method for controlling a membrane potential-dependent ion channel (VGSC or the like) through a type I taste receptor present in a nerve cell or the like. In the present invention, it has been found t...
|
|
WO/2023/237675A1 |
The present invention relates to vitamin B2 (riboflavin) for use in improving gut health in animals and humans. In particular, it was found that vitamin B2, upon delivery to the large intestine, increases the abundance of the beneficial ...
|
|
WO/2023/236864A1 |
Provided in the present invention are a BAF155 mutant gene and the pharmaceutical use thereof. Provided in the present invention are a BAF155 mutant or an active fragment thereof. Compared with wild-type BAF155, the BAF155 mutant or the ...
|
|
WO/2023/235928A1 |
Disclosed herein is a method of identifying an arrhythmogenic pluripotent stem cell-derived cardiomyocyte (PSC-CM), the method comprising: (i) determining whether CD200 is expressed on a surface of the PSC-CM; wherein if CD200 is express...
|
|
WO/2023/237511A1 |
The specification generally relates to uses of to uses of RXFP1 modulators, in particular methods of treating resistant hypertension and heart failure with pulmonary hypertension.
|
|
WO/2023/237684A1 |
The present invention relates to a combination comprising vitamin C and Lactobacillus rhamnosus and its use for improving gut health in animals and humans. It was found that a combination of vitamin C and Lactobacillus rhamnosus, when de...
|
|
WO/2023/237623A1 |
The present invention relates the use of an anti-inflammatory agent for inhibiting and/or preventing damage of a peripheral ganglion in a subject, particularly in a subject suffering from a cardiac disease. The present invention also rel...
|
|
WO/2023/237512A1 |
The specification generally relates to combinations of RXFP1 modulators and SGLT2 inhibitors, in particular pharmaceutical compositions comprising such combinations, and therapeutic methods using such combinations.
|
|
WO/2023/237542A1 |
Exacerbation of heart failure, better known as acute decompensated heart failure (HF), is characterized by dyspnea, edema and fatigue, and is a growing medical problem. The inventors demonstrated that transient O-GlcNAcase inhibition wou...
|
|
WO/2023/239727A1 |
The present disclosure provides certain LATS1 and/or LATS2 inhibitors, including selective LATS1/LATS2 inhibitors and dual LATS1/LATS2 and AKT inhibitors that are useful for the treatment of wounds, of diseases that would benefit from or...
|
|
WO/2023/239016A1 |
A composition containing demethylzeylasteral or a pharmaceutically acceptable salt thereof according to the present invention is a glucocorticoid receptor antagonist that inhibits intracellular glucocorticoid receptor activity and is hig...
|
|
WO/2023/237510A1 |
The specification generally relates to solid forms, for example, crystalline and amorphous forms, of (1S,4s)-4-(2-fluoro-4-methoxy-5-(((1S,2R,3S,4R)-3-(((1- methylcyclobutyl)methyl)carbamoyl)bicyclo[2.2.1]heptan-2-yl)
carbamoyl)phenoxy)-...
|
|
WO/2023/238074A1 |
Provided herein are methods and related compositions for enhancing or enhanced partial reprogramming of target cells in a subject in need thereof (e.g., a human subject suffering from or at risk of a disease), the method comprising admin...
|
|
WO/2023/236863A1 |
The present invention provides a deacetylation modified BAF155 protein and a pharmaceutical use thereof. The present invention provides a deacetylation modified BAF155 protein or an active fragment thereof. Compared with a wild-type BAF1...
|
|
WO/2023/231254A1 |
The present invention relates to the technical field of pharmaceutical compounds. Provided are avanafil phosphate compounds, the structural formula thereof being shown as formula I, wherein R in formula I is hydrogen, phenyl, substituted...
|
|
WO/2023/232997A1 |
The invention relates to a synergistic multi-ionic complex providing potentiated preventive and therapeutic responses to inflammation by modulating the pathways of immunity. It is a composition comprising mineral salts, including at leas...
|
|
WO/2023/232090A1 |
Provided is a pharmaceutical composition for treating hemorrhagic diseases, comprising: salvianolic acid as a first active ingredient; and ginsenoside as a second active ingredient. The pharmaceutical composition can be used for preventi...
|
|
WO/2023/233791A1 |
Provided are: an integrin activator that contains a substance that inhibits binding between a fibronectin and an immune inhibitory receptor LILRB4 as an active ingredient; and a therapeutic agent that contains a substance that inhibits b...
|
|
WO/2023/232643A1 |
The present invention relates to high-dose vitamin K2, in particular menaquinone-7 (MK- 7), for use in the treatment of coronary heart disease in high-risk subjects having a coronary artery calcification (CAC) score ≥400 (e.g. at the o...
|
|
WO/2023/234410A1 |
The present invention addresses the problem of providing: an inhibitory agent for myocardial cell death; and a prophylactic or therapeutic agent for myocardial disorders or heart failure. The problem is solved by an inhibitory agent for ...
|
|
WO/2023/232917A1 |
The invention relates to novel compounds having the general formula (Ib) or (Ib'), (Ib) or (Ib') wherein R1, R2, R6, A3, A4, A5, X, Y and W are as described herein, composition including the compounds and methods of using the compounds.
|
|
WO/2023/232054A1 |
Provided are a traditional Chinese medicine composition for treating cardiorenal syndrome and cardiac failure and a method for preparing same. The traditional Chinese medicine composition is prepared from the following raw materials: 3 t...
|
|
WO/2023/235502A1 |
This disclosure relates to novel pharmaceutical compositions comprising cyclohex-2- enylidene / 3, 3 -dimethylindoline compounds; a method of treating or ameliorating a cardiovascular disease or disorder, asthma, or narcolepsy in a subje...
|
|
WO/2023/232126A1 |
The present invention relates to use of a sesquiterpene polyketone compound and a salt thereof for preventing and treating pulmonary arterial hypertension. A biological activity experiment shows that the compound can reverse pulmonary va...
|
|
WO/2023/232984A1 |
The present invention pertains to an S100A1 protein, a biologically active fragment or variant thereof, to a nucleic acid encoding said S100A1 protein or said biologically active fragment or variant thereof, to a vector comprising said n...
|
|
WO/2023/233033A1 |
The present invention provides novel compounds of formula (I) and pharmaceutical compositions containing these compounds. The compounds of formula (I) can act as PAR-2 inhibitors, which renders these compounds highly advantageous for use...
|
|
WO/2023/233665A1 |
Provided are: an immunocyte activator containing, as an active ingredient, a substance which inhibits the binding of fibronectin and an immunosuppressive receptor LILRB4; and a therapeutic agent for immunocyte-related inflammatory diseas...
|
|
WO/2023/234678A1 |
The present invention relates to a pharmaceutical composition for preventing or treating a hypertensive disease, comprising isolated mitochondria as an active ingredient. When the pharmaceutical composition comprising isolated mitochondr...
|
|
WO/2023/234723A1 |
The present invention relates to a composition and treatment method for the prevention, treatment, or alleviation of vascular or plaque calcification diseases, wherein the composition contains 3-hydroxy niclosamide or a pharmaceutically ...
|
